Introduction
============

More patients with early breast cancer have been diagnosed with the development of screening techniques \[[@B1]\]. Following adjuvant chemotherapy and endocrine therapy can significantly improve disease-free survival (DFS) and overall survival (OS) in early breast cancer patients \[[@B2]-[@B4]\]. However, both adjuvant chemotherapy and endocrine therapy cause bone loss to these patients. Patients with amenorrhea after chemotherapy \[[@B5],[@B6]\] and postmenopausal patients receiving aromatase inhibitors (AIs) are at high risk of bone loss \[[@B3],[@B4],[@B7]-[@B9]\].

Zoledronic acid (ZOL) can prevent bone loss in early breast cancer patients \[[@B10]\]. Furthermore, ZOL also has antitumor and antimetastatic properties. The previous meta-analysis \[[@B11]\] suggested that the use of ZOL was associated with a statistically significant lower risk for disease recurrence. In addition, ZOL has several potential advantages compared to the oral bisphosphonates, including good bioavailability, gastrointestinal tolerance, and adequate compliance \[[@B12]\]. Thus, less adverse effects, such as gastrointestinal disorders and vascular disorders, were caused by ZOL \[[@B12]\]. However, the adverse effects caused by ZOL itself should not be neglected. Osteonecrosis of the jaw, an uncommon serious side effect caused by ZOL, has been paid close attention. Previous study \[[@B13]\] showed that osteonecrosis of the jaw occurred in only about 0.33% of patients treated with ZOL. Musculoskeletal disorders were common after ZOL administration and distressing to the patients. Up to now, no precise estimation of musculoskeletal disorders has been made. Previous randomized clinical trials \[[@B14]-[@B17]\] showed that musculoskeletal disorders occurred in more than 20% patients treated with ZOL and in more than 10% patients without ZOL treatment. Furthermore, some randomized trials \[[@B12],[@B18],[@B19]\] were conducted to evaluate the efficacy of upfront ZOL versus delayed ZOL in preventing bone loss. The musculoskeletal disorders reported by these trials were discordant.

The UK Expert Group \[[@B20]\] suggested that bisphosphonates should be administrated to patients with high risk of osteoporosis. However, patients with low risk of osteoporosis might benefit little from ZOL treatment. When ZOL was considered to be administrated to patients, the benefit and adverse effects should be well balanced. We performed this meta-analysis to give a precise estimation of the musculoskeletal disorders of ZOL versus no ZOL and upfront ZOL versus delayed ZOL in adjuvant breast cancer treatment.

Methods
=======

Search strategy
---------------

The present study was conducted as described previously \[[@B21]-[@B23]\]. Relevant studies were selected by searching the electronic database PubMed (updated on May 1, 2011), using the following terms: early or adjuvant, breast cancer or breast neoplasm, zoledronic acid or bisphosphonates. Two investigators (Zhou WB and Liu XA) independently evaluated titles and abstracts of the identified papers. References in identified articles and reviews were also reviewed for possible inclusion. Only published randomized clinical trials in English language were included in our study. Randomized clinical trials were included if they met the following criteria: (1) ZOL used in breast cancer patients in adjuvant setting; (2) ZOL used with a control group receiving no treatment or placebo, or upfront ZOL (receiving ZOL immediately after randomization) versus delayed ZOL (receiving ZOL only if *T*-score fell below -2.0, after a nontraumatic clinical fracture, or if an asymptomatic fracture); (3) enough published data for estimated a risk ratio (RR) with 95% confidence interval (CI). In addition, to avoid duplication of information, only the report with longest follow-up was included for calculations when multiple reports pertained to overlapping groups of patients.

Data extraction
---------------

The data of musculoskeletal disorders, including arthralgia, bone pain and muscle pain, were carefully extracted from all the eligible randomized trials independently by two investigators (Zhou WB and Liu XA). The following variables were extracted from each study: first author\'s name, the name of each trial, publication year, the median follow-up time, the number of total patients in every group, and the number of patients with musculoskeletal disorders in every group. All the data were reached consensus after discussion.

Statistical analysis
--------------------

Crude RRs with 95% CI were used to assess the musculoskeletal disorders risk of ZOL. The between-study heterogeneity was tested with Q statistics (significant differences indicated by *P*\< 0.10) \[[@B24]\]. The fixed-effects model (the Mantel-Haenszel method) was used when between-study was absent \[[@B25]\]. Otherwise, the random-effects model (the DerSimonian and Laird method) was selected \[[@B26]\]. Funnel plots and Egger\'s linear regression were used to test the publication bias and a *P*value less than 0.05 was considered significant. All analyses were performed using the software Stata version 11.0 (Stata Corporation, College Station, TX, USA).

Results
=======

Eligible studies
----------------

Ten randomized clinical trials, in which ZOL was used in adjuvant setting, were identified. Of these ten studies, the detail data of musculoskeletal disorders were not reported in three studies \[[@B27]-[@B29]\]. In all, seven studies \[[@B12],[@B14]-[@B19]\] were eligible in this meta-analysis. Table [1](#T1){ref-type="table"} presented the characteristics of the seven trials. Of these seven studies, four studies \[[@B14]-[@B17]\] reported musculoskeletal disorders of ZOL versus placebo or no treatment, including 2684 patients treated with ZOL and 2712 patients treated with placebo or no treatment. Three studies \[[@B12],[@B18],[@B19]\] reported the complications of upfront versus delayed ZOL, including 1091 patients with upfront ZOL and 1110 patients with delayed ZOL.

###### 

Characteristics of eligible trials

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (Study)       Year   Intervention               Dosage of treatment                                                                                 Duration (yr)   Number of patients   Follow-up (mo)
  -------------------- ------ -------------------------- --------------------------------------------------------------------------------------------------- --------------- -------------------- ----------------
  Gnant (ABCSG12)      2009   Zoledronic acid\           4 mg IV every 6 months                                                                              3               899\                 47.8
                              No treatment                                                                                                                                   904                  

  Shapiro (CALGB)      2011   Zoledronic acid\           4 mg IV every 3 months                                                                              NA              70\                  12
                              No treatment                                                                                                                                   80                   

  Hershman             2008   Zoledronic acid\           4 mg IV every 3 months                                                                              1               50\                  12
                              Placebo                                                                                                                                        53                   

  Coleman (AZURE)      2011   Zoledronic acid\           4 mg IV monthly for 6 months, then every 3 months for 8 doses and then every 6 months for 5 doses   5               1665\                6
                              No treatment                                                                                                                                   1675                 

  Brufsky (Z-FAST)     2009   Upfront zoledronic acid\   4 mg IV every 6 months                                                                              5               300\                 36
                              Delayed zoledronci acid                                                                                                                        300                  

  Eidtmann (ZO-FAST)   2010   Upfront zoledronic acid\   4 mg IV every 6 months                                                                              5               524\                 36
                              Delayed zoledronci acid                                                                                                                        536                  

  Hines (N03CC)        2009   Upfront zoledronic acid\   4 mg IV every 6 months                                                                              5               267\                 12
                              Delayed zoledronci acid                                                                                                                        274                  
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

yr, year; mo, months; IV, intravenous; NA, not available

ZOL versus no ZOL
-----------------

Table [2](#T2){ref-type="table"} showed the main results of this meta-analysis. Arthralgia occurred in about 23.9%-68% patients treated with ZOL and 12.5%-60.4% patients without ZOL treatment. Compared to patients without ZOL treatment, patients treated with ZOL had a significantly higher risk of arthralgia (RR: 1.162, 95% CI: 1.096-1.232, *P*= 0.466 for heterogeneity) (Figure [1](#F1){ref-type="fig"}). Bone pain occurred in about 35.3%-40% patients treated with ZOL and in 24.6%-41.5% patients without ZOL treatment. Similarly, a significantly higher risk of bone pain was observed in patients with ZOL treatment (RR: 1.257, 95% CI: 1.149-1.376, *P*= 0.193 for heterogeneity) (Figure [2](#F2){ref-type="fig"}). However, there was no significantly different risk of muscle pain between the two groups (RR: 1.198, 95% CI: 0.901-1.594, *P*= 0.366 for heterogeneity).

###### 

Summary RRs and 95% CI

  Complications   ZOL vs no ZOL                 Upfront ZOL vs delayed ZOL                                         
  --------------- ----------------------------- ---------------------------- --- ------------------------- ------- ---
  Arthralgia      **1.162 (1.096-1.232)^\#^**   0.466                        4   1.022 (0.932-1.120)       0.850   3
  Bone pain       **1.257 (1.149-1.376)**       0.193                        2   **1.284 (1.135-1.453)**   0.460   2
  Muscle pain     1.198 (0.901-1.594)           0.366                        2   1.071 (0.942-1.217)       0.422   3

RR, risk ratio; CI, confidence interval; ZOL, zoledronic acid;

\**P*value for between-study heterogeneity; \#the number in AZURE trial included the number of arthralgia and muscle pain.
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Funnel plot and Egger\'s test were performed to access the publication bias of the four studies. No significant publication bias (*P*\> 0.05) existed (data not shown).

Upfront versus delayed-start ZOL
--------------------------------

The main results were also showed in Table [2](#T2){ref-type="table"}. Arthralgia occurred in 12.7%-42.2% patients treated with upfront ZOL and in 11.3%-40.7% patients with delayed ZOL. There was no significantly different risk of arthralgia between the two groups (RR: 1.022, 95% CI: 0.932-1.120, *P*= 0.850 for heterogeneity). The similar results were observed about muscle pain between the two groups (RR: 1.071, 95% CI: 0.942-1.217, *P*= 0.422 for heterogeneity). The rates of muscle pain were 6.4%-16.3% and 5.1%-12.1% in upfront group and delayed group, respectively. Bone pain caused by ZOL was reported in Z-FAST and ZO-FAST trials. The rate of bone pain in upfront group (119/824) was significantly higher than that in delayed group (74/836) (RR: 1.284, 95% CI: 1.135-1.453, *P*= 0.460 for heterogeneity) (Figure [3](#F3){ref-type="fig"}).
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Since only three trials were included in this analysis of musculoskeletal disorders between upfront and delayed ZOL groups, publication bias was not accessed.

Discussion
==========

Previous randomized clinical trials showed that musculoskeletal disorders occurred in a high rate of patients treated with ZOL. This meta-analysis suggested that patients treated with ZOL had a statistically significant higher risk of arthralgia and bone pain compared to patients without ZOL treatment. Furthermore, patients treated with upfront ZOL had a significant higher risk of bone pain than patients with delayed ZOL.

Although ZOL can bypass the potential disadvantages of the oral route used by other bisphosphonates, it may cause more musculoskeletal disorders than other bisphosphonates \[[@B30]-[@B32]\]. A high rate of musculoskeletal disorders occurred in patients treated with ZOL. Patients treated with ZOL had a statistically significant higher risk of arthralgia and bone pain than patients without ZOL treatment. These adverse effects bring anxiety to patients and may threaten patients\' life quality in some conditions. These adverse effects generally resolve within 48 hours and respond well to nonsteroidal anti-inflammatory drugs \[[@B33]\]. Of these patients, some suffered serious musculoskeletal disorders from ZOL treatment, which exist longer and respond worse to anti-inflammatory drugs. Sometimes, serious musculoskeletal disorders cause treatment withdrawal. Although most musculoskeletal disorders will disappear spontaneously, we should take more attentions to patients treated with ZOL. The dose, frequency, and speed of infusion are all important determinants of these adverse effects \[[@B33]\]. When patients with high risk of osteoporosis suffered serious musculoskeletal disorders from ZOL, the risk-reducing measures should be considered. These measures included reducing the dose, slowing the infusion rate and prolonging the interval between infusions. When the patients can not tolerate these adverse effects, other oral bisphosphonates should be considered \[[@B33]\]. When ZOL was administrated to patients with low risk of osteoporosis, little benefit but additional musculoskeletal disorders would be brought to these patients.

Three randomized clinical trials \[[@B12],[@B18],[@B19]\] were conducted to compare upfront ZOL with delayed ZOL for prevention of bone loss in postmenopausal women. These studies suggested that upfront ZOL was more effective in preserving bone mineral density than delayed ZOL, but no significant difference in fracture rate was observed. The UK Expert Group \[[@B20]\] suggested that patients with low risk of osteoporosis did not need a special treatment, while patients with high risk should be treated with bisphosphonates. Our results suggested more musculoskeletal disorders were observed in patients treated with upfront ZOL. Since not all patients need upfront ZOL treatment, delayed ZOL may be considered preferentially in some conditions. In addition, although ZO-FAST trial showed that upfront ZOL led to improved DFS, further randomized trials are required to investigate the survival and adverse effects between upfront ZOL and delayed ZOL.

Several limitations of this meta-analysis should be considered when interpreting these results. First, of these seven studies, most subjects were Caucasians, while seldom Asians were included. Second, the present results were based on unadjusted RRs. More precise estimation may be adjusted by other potential covariates. Third, due to lack of data on musculoskeletal disorders, three trials were excluded. Since these studies were with small sample size, they were unlikely to change significantly our results.

Conclusions
===========

This meta-analysis strongly suggested that patients treated with ZOL had a statistically significant higher risk of arthralgia and bone pain than those without ZOL treatment. Furthermore, patients treated with upfront ZOL had a significantly higher risk of bone pain than patients with delayed ZOL. More attentions should be paid to patients with musculoskeletal disorders. For patients with low risk of osteoporosis, immediate ZOL may be not needed due to additional adverse effects in some conditions. Or it can be stopped after the occurrence of these adverse events. Further randomized clinical trials with large sample size should be taken to evaluate the side effects of ZOL, especially for musculoskeletal disorders.
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